| Methods |
Randomized controlled trial |
| Participants |
Patients with active inflammatory bowel disease (ulcerative colitis N = 30, or Crohn's disease N = 30) |
| Interventions |
Oral 5‐ASA, 0.5 g three times daily (n = 15) or oral SASP, 1.0 g three times daily (n = 15) for 8 weeks |
| Outcomes |
Remission and clinical improvement |
| Notes |
Study also enrolled 30 patients with Crohn's disease |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
| Selective reporting (reporting bias) |
Unclear risk |
Not described |
| Other bias |
Unclear risk |
Not described |
